Target intelligence / Profile preview

T-cell receptor CD3 zeta chain (CD3ζ)

Target
CD3ζ
Molecular classification
Receptor-associated signaling subunit, Immunoreceptor tyrosine-based activation motif (ITAM) containing protein, Part of the T cell receptor (TCR)/CD3 complex, Transmembrane signaling protein
01

Overview

The T-cell receptor CD3 zeta chain (CD3ζ) is a critical component of the TCR/CD3 complex on T lymphocytes, required for TCR expression, stability, and signal transduction. It forms ζζ homodimers that partner with other CD3 subunits (CD3δ, CD3γ, and CD3ε), embedding three ITAMs within its intracellular domain. Upon antigen recognition by the TCR, these ITAM motifs initiate downstream signaling by recruiting kinases such as LCK and ZAP-70, leading to T cell activation. Loss or diminished expression of CD3ζ results in impaired TCR transport, degradation of incomplete receptor complexes, and decreased function of T cells. Therapeutically, CD3ζ is targeted to modulate immune responses in contexts ranging from cancer immunotherapy to transplantation.

Other names
CD3 zeta chainCD247 (gene name)CD3ζTCR zeta chain
02

Mechanism of action

Immunomodulation — Monoclonal antibodies such as muromonab-CD3 bind the CD3 complex (including CD3ζ), resulting in T cell depletion or modulation via activation-induced apoptosis or anergy. Signal enhancement — Genetic enhancement or supplementation of CD3ζ in engineered T cells increases TCR surface expression and improves antigen-specific function.

03

Biological functions

Signal transduction (initiates TCR-mediated signaling via its ITAMs, leading to downstream activation of kinases such as LCK and ZAP-70)Immune response (central to antigen recognition and T cell activation)Assembly and surface expression of TCR (essential for proper transport and stability of the TCR/CD3 complex on the T cell membrane)
04

Disease associations

Cancer (decreased CD3ζ expression is observed in dysfunctional, tumor-infiltrating T cells)Infection (general T cell activation is required to combat pathogens)Other immune-related diseases (deficiency or mutation can lead to immunodeficiencies/immune dysregulation)
05

Safety considerations

Cytokine release syndromeImmunosuppression and infection riskTCR mispairing
06

Interacting drugs

Monoclonal antibodies targeting CD3 (e.g., OKT3, muromonab-CD3)

1 more in the full profile.

07

Biomarkers

CD3ζ expression levels

Beyond the preview

Go deeper on T-cell receptor CD3 zeta chain (CD3ζ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell receptor CD3 zeta chain (CD3ζ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call